Deutsche Bank
MLTX icon

Deutsche Bank’s MoonLake Immunotherapeutics MLTX Stock Holding History

Deutsche Bank’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.2K Buy
2,888
+836
+41% +$15.2K ﹤0.01% 3559
2026
Q1 		$38.2K Hold
2,052
– – ﹤0.01% 3500
2025
Q4 		$27K Sell
2,052
-288
-12% -$3.4K ﹤0.01% 3504
2025
Q3 		$16.8K Buy
2,340
+785
+50% +$40.9K ﹤0.01% 3509
2025
Q2 		$73.4K Buy
1,555
+652
+72% +$26.6K ﹤0.01% 3359
2025
Q1 		$35.3K Hold
903
– – ﹤0.01% 3430
2024
Q4 		$48.9K Buy
903
+338
+60% +$17.3K ﹤0.01% 3415
2024
Q3 		$28.5K Hold
565
– – ﹤0.01% 3441
2024
Q2 		$24.8K Hold
565
– – ﹤0.01% 3409
2024
Q1 		$28.4K Hold
565
– – ﹤0.01% 3477
2023
Q4 		$34.1K Buy
+565
New +$29.1K ﹤0.01% 3455

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Deutsche Bank's MLTX Position: Q2 2026 in Review

Deutsche Bank increased its MoonLake Immunotherapeutics (MLTX) stake by 41% in Q2 2026, buying an estimated $15.2K and bringing the position to 2,888 shares worth $56.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3559.

Deutsche Bank first reported a position in MLTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $73.4K in Q2 2025. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Deutsche Bank held 2,888 shares of MoonLake Immunotherapeutics worth $56.2K as of Q2 2026.
  • Deutsche Bank bought 836 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $15.2K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3559 holding.
  • Deutsche Bank first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 11 quarters since.
  • Deutsche Bank's MoonLake Immunotherapeutics position peaked at $73.4K in Q2 2025.
  • 172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.